PBTZ 169Alternative Names: PBTZ169
Latest Information Update: 06 Feb 2017
At a glance
- Originator A. N. Bach Institute of Biochemistry; Ecole Polytechnique Federale de Lausanne.
- Developer Ecole Polytechnique Federale de Lausanne.; NEARMEDIC
- Class Antituberculars
- Mechanism of Action Cell wall inhibitors; DprE1 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Tuberculosis